Navigation Links
Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
Date:2/25/2008

Regenerative Medicine Leader Strengthens Scaffold-Engineering Capabilities

with Electrospinning Platform Technology & Team

CANTON, Mass. and BATON ROUGE, La., Feb. 25 /PRNewswire/ -- Organogenesis, Inc., the world's most successful regenerative medicine company, announced today the strategic acquisition of Baton Rouge-based NanoMatrix, Inc.

NanoMatrix's platform technology develops "designer scaffolds" for the purposes of regenerative medicine, based on the fabrication technique known as electrospinning. Electrospinning is a novel method of producing and assembling nano-scale fibers into three-dimensional scaffolds, which mimic the structure and biochemical environment of the human body's tissues. NanoMatrix's core technology makes it possible to mimic the three-dimensional architectural structure that is essential for the body's natural growth and repair processes.

"This acquisition strengthens Organogenesis' position as the leading innovator in developing three-dimensional regenerative medicine constructs," said Geoff MacKay, CEO of Organogenesis. "The technology platforms of Organogenesis and NanoMatrix are highly complementary. Our innovative electrospinning techniques enable researchers to develop the most cell-friendly scaffolds and physiologically-realistic tissues to date, translating into greater clinical benefit for the patient."

William C. Fioretti, Ph.D., Chairman of NanoMatrix, said, "We are very pleased with the acquisition by Organogenesis, which has the team, experience in cellular therapy, and the vision to maximize the platform technology's potential. Our technology can be used to have a significant impact on biomatrix materials and patient care, and this transaction assures that it will come to market. "

Organogenesis is the first company to successfully mass-produce living regenerative medicine products, reaching hundreds of thousands of patients. Its signature product, Apligraf(R), is the first bio-engineered cell therapy to have received FDA approval, and is used by doctors successfully in treating patients with diabetic foot ulcers and venous leg ulcers in the U.S. and other markets across the world.

In addition to acquiring NanoMatrix's platform technology, intellectual property and commercial-scale equipment, Organogenesis gains NanoMatrix veteran talent, including Gary Cadd, Ph.D. Gary brings with him more than 17 years of biomaterials research, and has already assembled a team within Organogenesis' Research & Development department to adapt the technology to the Company's core business.

Originally developed by scientists at Virginia Commonwealth University, NanoMatrix's electrospinning capabilities are broad and versatile. Scaffolds can be fabricated from both natural and synthetic polymers (anything from collagen to polypropylene) and can even be manufactured into different sizes and shapes, including tubes, mats and coatings, among others. The fibers comprising the scaffold can be custom-engineered to a specific orientation (parallel / perpendicular) or thickness, including on the "nanometer" scale (a thousand times thinner than a human hair). What results from these capabilities is an implantable scaffold with the correct fiber diameter, orientation and architecture, rendered virtually indistinguishable from native tissue and recognized as "self" by the body.

However, electrospinning is not limited to polymers. Other elements of regenerative medicine, including cells, drugs and bioactive factors, can be combined into the scaffold. In fact, electrospinning is an area of intense focus for academic biomaterials research, validating the importance of this technology platform. While the collagen nanofiber is the core of NanoMatrix's proprietary technology, its patents also cover many different synthetic bioabsorbable polymer types and blends.

"Researchers have used electrospinning techniques to produce a variety of material, including vascular grafts, nerve guides, tendon and skin," continued MacKay. "With such expansive capabilities, the list of applicable indications for electrospinning is vast."

About Regenerative Medicine

A new frontier in healthcare, regenerative medicine is an evolving therapeutic approach that utilizes living cells to repair or replace body tissue damaged by injury, disease or the aging process. It is a multidisciplinary field involving biology, medicine and engineering.

Regenerative therapies rely on the body's own natural ability to repair and regenerate, and enable the body to heal itself Regenerative medicine also empowers scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.

About Organogenesis, Inc.

Massachusetts based Organogenesis, Inc. is the world's most successful regenerative medicine company and is focused in areas of bio-active wound healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue "on demand," and its mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit http://www.organogenesis.com.


'/>"/>
SOURCE Organogenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology:
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
Breaking Biology News(10 mins):